|Bid||8.84 x 800|
|Ask||8.90 x 900|
|Day's range||8.44 - 8.98|
|52-week range||6.97 - 16.60|
|Beta (5Y monthly)||1.53|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.22|
DURHAM, N.C., December 06, 2021--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting from the PBCAR0191 CD19 allogeneic CAR T program and provide other CAR T program updates during a company-hosted webcast and conference call on Saturday, Decem
Bayer's (BAYRY) phase III study evaluating Nubeqa in combination with docetaxel and androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer meets the primary endpoint.
Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.